PDCD1 and breast cancer: Therapeutic antibodies that disrupt the PD-1/PD-L1 axis restore T cell activity and have shown clinical benefits in melanoma [5,6,7,8], non-small-cell lung cancer [9], bladder cancer [10], breast cancer [11], urothelial carcinoma [12,13], and other malignancies.